Stock Movers NatWest Rises, GSK Drops, Accor Up
Oct 24, 2025
Louise Moon, Breaking News Editor at Bloomberg, shares her insights on the latest movements in European stocks. She highlights NatWest's impressive Q3 performance, attributing its surge to a decade-high profit and strong cost control. In contrast, GSK faces challenges after its blood cancer drug approval raised concerns over sales potential. Meanwhile, Accor celebrates a positive earnings report and boosts confidence by announcing a €100 million buyback, showcasing its commitment to financial discipline.
AI Snips
Chapters
Transcript
Episode notes
NatWest's Earnings Power Surges
- NatWest delivered its highest earnings in at least a decade, driven by higher interest rates and cost control.
- Investors pushed the stock to a 15-year high reflecting confidence in its digital simplification and resilience.
Blenrep Approval Comes With Limits
- GSK secured US approval for Blenrep but with narrower eligible use than expected.
- Markets trimmed GSK shares because the approval limits the drug's commercial upside and sales potential.
Accor Ups Guidance And Returns
- Accor raised guidance after third-quarter results and credited cost discipline and portfolio simplification.
- The hotel group also announced a €100m buyback and may list its lifestyle brands to boost shareholder returns.